Loss of MEG3 expression is associated with Cisplatin Resistance in lung Adenocarcinoma.

Downregulation of Meg3 enhances cisplatin resistance of lung cancer cells through activation of the WNT/beta-catenin signaling pathway.

Data suggest that mternally expressed gene 3 (Meg3) long non-coding RNA and microRNA miR-3163 may coordinate suppression of translation of S-phase kinase associated protein 2 (Skp2) mRNA in non-small cell lung cancer (NSCLC) cells to inhibit cell growth.

Inactivation of retinoblastoma protein leads to decreased expression of MEG3 and re-expression inhibits proliferation in human lung adenocarcinoma cells.

Overexpression of MEG3 is associated with Epithelial-Mesenchymal Transition in lung cancer.

The results indicate that the MEG3 rs4081134 polymorphism was significantly associated with lung cancer susceptibility in the Chinese population.

Results showed that lncRNA MEG3 expression was significantly decreased in non-small cell lung cancer (NSCLC) , and it was involved in the occurrence of NSCLC through lncRNA MEG3/microRNA-7/BRCA1 pathway.

Long noncoding RNA MEG3 plays a promoting role in the proliferation, invasion, and angiogenesis of lung adenocarcinoma cells through the AKT pathway.

MEG3/miR-650/SLC34A2 axis may be implicated in stem cell-like state and cell migration and invasion in lung cancer stem cells.

Long noncoding RNA MEG3 inhibits cell migration and invasion of nonsmall cell lung cancer cells by regulating the miR215p/PTEN axis.